804 related articles for article (PubMed ID: 27227483)
1. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
2. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
Daudt L; Maccario R; Locatelli F; Turin I; Silla L; Montini E; Percivalle E; Giugliani R; Avanzini MA; Moretta A; Montagna D
J Immunother; 2008 May; 31(4):385-93. PubMed ID: 18391757
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes.
Lu J; Giuntoli RL; Omiya R; Kobayashi H; Kennedy R; Celis E
Clin Cancer Res; 2002 Dec; 8(12):3877-84. PubMed ID: 12473603
[TBL] [Abstract][Full Text] [Related]
5. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
Oh S; Perera LP; Burke DS; Waldmann TA; Berzofsky JA
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15154-9. PubMed ID: 15477598
[TBL] [Abstract][Full Text] [Related]
6. Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response.
Khan IA; Moretto M; Wei XQ; Williams M; Schwartzman JD; Liew FY
J Exp Med; 2002 Jun; 195(11):1463-70. PubMed ID: 12045244
[TBL] [Abstract][Full Text] [Related]
7. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
8. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
[TBL] [Abstract][Full Text] [Related]
10. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
Stoklasek TA; Schluns KS; Lefrançois L
J Immunol; 2006 Nov; 177(9):6072-80. PubMed ID: 17056533
[TBL] [Abstract][Full Text] [Related]
11. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
13. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
Hasan AN; Kollen WJ; Trivedi D; Selvakumar A; Dupont B; Sadelain M; O'Reilly RJ
J Immunol; 2009 Aug; 183(4):2837-50. PubMed ID: 19635907
[TBL] [Abstract][Full Text] [Related]
14. Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.
Miyao K; Terakura S; Okuno S; Julamanee J; Watanabe K; Hamana H; Kishi H; Sakemura R; Koyama D; Goto T; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2018 Jun; 6(6):733-744. PubMed ID: 29653982
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells.
Schluns KS; Williams K; Ma A; Zheng XX; Lefrançois L
J Immunol; 2002 May; 168(10):4827-31. PubMed ID: 11994430
[TBL] [Abstract][Full Text] [Related]
16. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
18. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy.
Chamucero-Millares JA; Bernal-Estévez DA; Parra-López CA
Cell Immunol; 2021 Feb; 360():104257. PubMed ID: 33387685
[TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
